In this article, we will discuss Durvalumab (Dosage Modifications-4). So, let’s get started.
Hepatitis with tumor
involvement of the liver
AST or ALT is more than 1 and up
to 3 times ULN at baseline and
increases to more than 5 and up to 10 times ULN or AST or ALT is
more than 3 and up to 5 times ULN at baseline and increases to more than 8 and up to 10 times ULN – Withhold
AST or ALT increases to more
than 10 times ULN or Total bilirubin increases to more than 3 times ULN – Permanently discontinue